People's Republic of China (PRC) and ADB
ADB’s operations in the People’s Republic of China help develop innovative solutions to address complex development challenges and provide lessons and models for replication in other ADB developing member countries.
ADB's COVID-19 Response is a $20 billion package to support its developing member countries in countering the severe macroeconomic and health impacts caused by COVID-19, including $2.5 billion in concessional and grant resources, as well as $2 billion earmarked for the private sector (nonsovereign).
The Asia Pacific Vaccine Access Facility (APVAX) is ADB's $9 billion vaccine initiative offering rapid and equitable support to its developing member countries as they procure and deliver effective and safe COVID-19 vaccines.
Committed Amount is the financing approved by ADB's Board of Directors or Management for which the legal agreement has been signed by the borrower, recipient, or the investee company and ADB.
*The number of projects excludes short-term finance transactions under the Trade Finance, Supply Chain Finance, and Microfinance Programs.
This working paper explores the benefits and trade-offs of harnessing private sector health services as governments look to build more resilient, accessible, and affordable health systems and support the post-pandemic recovery.
This guidance note provides a comprehensive overview of medical oxygen production, distribution, and use in Asia and the Pacific region, and explores how to improve systems over the medium and long term.
This brief analyzes how the COVID-19 pandemic has impacted labor migrants in Asia and the Pacific, assesses the socioeconomic vulnerabilities it exposed, and lays out steps to better protect overseas workers.
This guidance note is designed to help developing member countries of the Asian Development Bank strengthen their health systems and security as they recover from the impact of COVID-19.